logo/base Created with Sketch.

Our
solutions
for
clinical
trials

Our Expertise and Turn-Key solutions supporting each step of your trial and driving success

wave
wave

Best-in-class liver NIT
for every phase of your trial

SCREENING
Use of LSM by VCTE™, CAP™ and Fast to pre-screen patients
and significantly reduce biopsy screen failure rate.

MONITORING
FibroScan® and Scores provide capabilities to monitor treatment response.

PROGNOSIS
Predict liver-related events with LSM by VCTE™ and Agile 3+

PHASE IV & MASH F4
Use of LSM by VCTE™, Agile 4 score, and SSM by VCTE™ to rule-in presence of cirrhosis.

Our solutions allow you to collect as much data as possible on non-invasive tests to build up evidence to support the removal of liver biopsy as a primary endpoint.

Unique secured service:
de-risking execution, ensuring consistency

ASSESSMENT & RECOMMENDATIONS
We support you in qualifying clinical sites (surveys, project management) and accelerate their readiness to meet timelines for site activation.

CUSTOMIZED SITES & OPERATORS TRAINING
The standardization of sites and operator capabilities maximizes the performances of FibroScan® solutions.

IN-TRIAL QUALITY CONTROL
We review every exam uploaded on our cloud secured platform to identify potential deviation in FibroScan® capabilities and proactively act to ensure data consistency.

QUALITY CONTROL DATA
On average, we observed that 20%of exams are flagged as low quality and 4-5% require a repeat after sponsor validation. In trial Exam quality is proven to improving up to 25% within 6 months of FibroScan® Quantity Control implementation.

Preparing for commercialization

Enlarge diagnostic capacity when your drugs hit the market with
a cost-effective test, associated workflow and established recognition.

Echosens is engaged with many sponsors in screening
and monitoring patients for clinical trials in MASLD/MASH.
More than 1,000 clinical institutions chose FibroScan® for their trials.

Dedicated White Paper

With clinical data, evidences and figures, this white paper illustrates how FibroScan® and its associated solutions are used by the Pharmaceutical Industry and Clinical Research Organizations for drug development purposes.

Dedicated Webinar

Watch our webinar to learn how FibroScan® Solutions can support through all the steps of your trial journey. Professor Castera reviews the benefits of FibroScan® and its composite Scores in late-phase MASH trials, including showing the capability to significantly reduce screen failure rates, monitor patients, and accelerate confirmation as a clinical benefit.
On top of the NITs usage, the Echosens team presents how we partner with the clinical sites and sponsors to implement robust quality control processes to support standardization of FibroScan® data.